Heck Capital Advisors LLC Makes New Investment in Edwards Lifesciences Co. (NYSE:EW)

Heck Capital Advisors LLC purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,179 shares of the medical research company's stock, valued at approximately $309,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences in the fourth quarter worth $26,000. Vega Investment Solutions acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $27,000. Millstone Evans Group LLC bought a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $30,000. Finally, Catalyst Capital Advisors LLC acquired a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $54,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 1.4%

Shares of NYSE EW traded up $1.06 during mid-day trading on Thursday, reaching $77.72. 4,110,804 shares of the company's stock traded hands, compared to its average volume of 5,155,349. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The business has a 50-day simple moving average of $73.09 and a 200 day simple moving average of $72.25. The stock has a market cap of $45.59 billion, a P/E ratio of 11.15, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company's quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.66 EPS. On average, analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on EW shares. Wall Street Zen cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Friday, May 16th. Morgan Stanley increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Barclays increased their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a research note on Friday, April 25th. Finally, Evercore ISI decreased their target price on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of "Hold" and a consensus price target of $80.20.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 400 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the transaction, the vice president now owns 22,588 shares in the company, valued at approximately $1,569,414.24. This represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares in the company, valued at approximately $4,106,859.33. The trade was a 9.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 67,692 shares of company stock valued at $4,822,074. Insiders own 0.34% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.